Q00987 (MDM2_HUMAN) Homo sapiens (Human)

E3 ubiquitin-protein ligase Mdm2 UniProtKBInterProSTRINGInteractive Modelling

491 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5; Isoform 6; Isoform 7; Isoform 8; Isoform 9; Isoform 10; Isoform 11)

Available Structures

139 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Structure of complex of MDM2(3-109) and P73 TAD(10-25)
2mps
 Heteromer
O15350; 		3-109
Assess
Green fluorescent protein linked MTide-02 inhibitor in complex with mdm2
5wts
 Heteromer
15-110
1×GOL; 2×PO4; 1×PG4;
Assess
Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide, altern…
8f13
 Heteromer
17-111
6×EDO; 1×SO4; 1×DMS; 1×WHL;
Assess
MDM2 bound CueO-PM2 sensor
6im9
 Heteromer
P36649; 		25-111
Assess
Structure of the MDM2 P53 binding domain in complex with H101, an all-D Helicon Polypeptide
8f0z
 Heteromer
25-110
1×CL; 1×WHL;
Assess
Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H330, a Helicon P…
8eic
 Heteromer
P35222; 		25-110
1×WHL;
Assess
Crystal structure of the computationally designed chemically disruptable heterodimer LD6-MDM2
7aye
 Heteromer
Q328D2; 		25-110
Assess
Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H329, a Helicon P…
8eib
 Heteromer
P35222; 		25-110
1×WHL;
Assess
Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H332, a Helicon P…
8ei9
 Heteromer
P35222; 		25-110
1×WHL;
Assess
Crystal structure of p53 epitope-scaffold based on a inhibitor of cysteine proteases in complex wit…
5swk
 Heteromer
26-110
7×CL; 2×SO4; 1×GOL;
Assess
MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53
1ycr
 Heteromer
P04637; 		25-109
Assess
Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H333, a Helicon P…
8eia
 Heteromer
P35222; 		26-110
1×WHL;
Assess
Crystal structure of human MDM2 in complex with a potent miniature protein inhibitor (18-residues)
3iux
 Heteromer
27-109
3×ACT; 1×CL;
Assess
Crystal Structure of an MDM2/P53 Peptide Complex
4hfz
 Heteromer
P04637; 		26-108
1×SO4;
Assess
Solution structure of Hdm2 with engineered cyclotide
2m86
 Heteromer
27-109
Assess
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer
2vjf
 Heteromer
O15151; 		428-491
4×ZN;
Assess
Structure of MDM2-MDMX-UbcH5B-ubiquitin complex
5mnj
 Heteromer
O15151; P0CG47; P62837; 		429-491
4×ZN; 1×SO4;
Assess
Crystal structure of human MDM2 RING domain homodimer bound to UbcH5B-Ub
6sqo
 Heteromer
P62837; P62979; 		430-491
4×ZN; 4×CL; 2×NO3;
Assess
Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 1)
7ai0
 Heteromer
P0CG47; P62837; 		430-491
4×CL; 2×ZN; 2×EDO;
Assess
Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 2)
7ai1
 Heteromer
P0CG47; P62837; 		430-491
1×CL; 2×ZN; 2×EDO;
Assess
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer
2vje
 Heteromer
O15151; 		432-491
4×ZN;
Assess
Crystal structure of human MDM2-RPL11
4xxb
 Heteromer
P62913; 		293-334
1×IMD; 1×BME; 2×ZN;
Assess
human MDM2-5S RNP
8bgu
 Heteromer
P46777; P62913; 		293-334
1×ZN;
Assess
Human 14-3-3 sigma in complex with human MDM2 peptide
8p0d
 Heteromer
P31947; 		164-187
2×GOL; 2×PEG; 2×CL; 4×MG;
Assess
Crystal Structure of the USP7:Hdm2(PSTS) complex
3mqs
 Heteromer
Q93009; 		395-401
Assess
14-3-3 sigma in complex with hDM2-186 peptide
6yr6
 Heteromer
P31947; 		183-188
6×IOD;
Assess
The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with mdm2 peptide 147-150
2fop
 Heteromer
Q93009; 		145-150
Assess
CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR
1rv1
homo-3-mer25-109
5×IMZ;
Assess
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.
5j7f
homo-2-mer11-111
2×6GG;
Assess
Structure of Human MDM2 in complex with a Benzodiazepine Inhibitor
1t4e
homo-2-mer16-111
2×DIZ;
Assess
Structure of a stapled peptide antagonist bound to Nutlin-resistant Mdm2.
4umn
homo-2-mer18-112
Assess
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.
5j7g
homo-2-mer18-111
2×6GG;
Assess
Inhibitor of MDM2-p53 Interaction
7bj0
homo-2-mer17-110
2×TVH;
Assess
X-ray structure of the p53-MDM2 inhibitor NMI801 bound to HDM2 at 2.1A resolution
6i29
homo-2-mer19-111
2×H0W;
Assess
Structure of hMDM2 in complex with Nutlin-3a-aa
8aeu
homo-2-mer25-111
2×BME; 2×M0L;
Assess
Crystal structure of human MDM2 with a 12-mer peptide inhibitor PMI (N8A mutant)
3lnz
homo-2-mer25-109
2×CL;
Assess
Structure of hDM2 with Dimer Inducing Indolyl Hydantoin RO-2443
3vbg
homo-2-mer25-109
2×03M;
Assess
Crystal structure of human MDM2 in complex with a 12-mer peptide inhibitor
3eqs
homo-2-mer26-109
2×GAI;
Assess
Crystal structure of human MDM2 in complex with D-peptide inhibitor (DPMI-alpha)
3lnj
homo-2-mer26-108
1×SO4; 1×CL;
Assess
Solution Structure of Hdm2 RING Finger Domain
2hdp
homo-2-mer429-491
4×ZN;
Assess
NMR Structure of Mdm2 (6-125) with Pip-1
2lzg
monomer1-125
1×13Q;
Assess
NMR structure of unliganded MDM2
1z1m
monomer1-118
Assess
Ordering of the N Terminus of Human MDM2 by Small Molecule Inhibitors
4hbm
monomer6-111
1×0Y7;
Assess
Co-crystal Structure of MDM2 in Complex with AM-7209
4wt2
monomer6-110
1×3UD; 2×SO4;
Assess
Co-Crystal Structure of MDM2 with Inhibitor Compound 4
4ode
monomer6-110
1×2U0; 2×SO4;
Assess
MDM2 in complex with SAR405838
5trf
monomer10-111
1×7HC; 1×SO4; 3×GOL;
Assess
Co-Crystal Structure of MDM2 with Inhbitor Compound 3
4ogn
monomer11-110
1×2U5; 2×SO4;
Assess
Co-Crystal Structure of MDM2 with Inhbitor Compound 46
4ogt
monomer12-110
1×2U6; 1×SO4;
Assess
Co-Crystal Structure of MDM2 with Inhibitor Compound 47
4odf
monomer12-110
1×2U1;
Assess
Chemical Shift Assignments for MIP and MDM2 in bound state
2ruh
monomer6-102
Assess
Structure of the stapled peptide YS-01 bound to MDM2
4ue1
monomer17-112
Assess
Structure of the stapled peptide YS-02 bound to MDM2
4ud7
monomer17-112
Assess
HDM2 in complex with a 3,3-Disubstituted Piperidine
5hmi
monomer18-113
1×62T; 1×SO4;
Assess
Structure of MDM2 with low molecular weight inhibitor
5oai
monomer18-113
1×B5K;
Assess
Human MDM2 liganded with a 12mer peptide inhibitor (pDI6W)
3jzr
monomer17-112
Assess
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-bas…
5ln2
monomer17-111
1×6ZT; 1×SO4; 1×CL;
Assess
Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids
5xxk
monomer18-112
Assess
HDM2 in complex with compound 63
7na4
monomer17-111
1×1I9; 2×GOL; 1×CL;
Assess
Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide
8f12
monomer17-111
2×SO4; 1×CL; 1×WHL;
Assess
HDM2 in complex with compound 56
7na2
monomer17-111
1×1I0;
Assess
Structure of Mdm2 with low molecular weight inhibitor
4zfi
monomer18-112
1×4NJ;
Assess
HDM2 in complex with compound 62
7na3
monomer17-111
1×1I3; 4×SO4;
Assess
Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of t…
5lay
monomer17-111
3×GOL; 1×SO4; 1×6SS;
Assess
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 9 AT 1.13A; Structural states of Hdm2 and HdmX: X-r…
6q9l
monomer18-111
1×HTZ; 3×CL;
Assess
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 10 AT 1.21A; Structural states of Hdm2 and HdmX: X-…
6q9o
monomer17-110
1×HU8;
Assess
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…
5law
monomer18-111
1×6SJ; 3×SO4;
Assess
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…
5laz
monomer18-111
1×6ST; 1×ZN; 1×SO4;
Assess
Crystal structure of MDM2 in complex with compound 13.
6i3s
monomer18-111
1×H28; 1×GOL; 2×SO4;
Assess
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor
6ggn
monomer18-111
1×EYH; 1×CL;
Assess
HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A
5oc8
monomer19-111
1×9QW; 1×CL;
Assess
Structure of human MDM2 protein in complex with Mi-63-analog
3lbl
monomer18-110
1×MI6;
Assess
Exhaustive Fluorine Scanning towards Potent p53-MDM2 Antagonist
3tu1
monomer18-110
1×07G;
Assess
Co-crystal structure of MDM2 with inhibitor (2'S,3R,4'S,5'R)-N-(2-aminoethyl)-6-chloro-4'-(3-chloro…
4jvr
monomer18-110
1×1MT;
Assess
co-crystal structure of MDM2 (17-111) in complex with compound 25
4oas
monomer18-110
1×2SW;
Assess
co-crystal structure of MDM2 (17-111) with compound 16, {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP…
4qo4
monomer18-110
1×35S;
Assess
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…
5lav
monomer19-111
1×6SK; 1×SO4;
Assess
HDM2 in complex with a 3,3-Disubstituted Piperidine
5hmh
monomer21-113
1×62R; 1×SO4;
Assess
co-crystal structure of MDM2(17-111) in complex with compound 48
4occ
monomer18-110
1×2TZ;
Assess
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical …
4zyf
monomer18-110
1×4T4; 1×CL;
Assess
The Central Valine Concept Provides an Entry in a New Class of Non Peptide Inhibitors of the P53-MD…
4dij
monomer18-110
1×BLF;
Assess
Structure of a novel submicromolar MDM2 inhibitor
4mdn
monomer18-110
1×Y30; 2×SO4;
Assess
Structure of Mdm2 with low molecular weight inhibitor.
4zgk
monomer18-110
1×4NX;
Assess
crystal structure of MDM2 with chromenotriazolopyrimidine 1
3jzk
monomer18-110
1×YIN;
Assess
Co-Crystal Structure of MDM2 with Inhibitor Compound 49
4ogv
monomer18-110
1×2U7;
Assess
Co-crystal structure of MDM2 with inhibitor (2R,3E)-2-[(2S,3R,6S)-2,3-bis(4-chlorophenyl)-6-(4-fluo…
4jve
monomer18-110
1×1MQ;
Assess
Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction
4oq3
monomer18-110
1×2V8;
Assess
Crystal Structure of HDM2 in complex with Nutlin-3a
5c5a
monomer20-111
1×NUT; 1×SO4; 1×CL; 1×IOD;
Assess
HDM2 in complex with a beta-hairpin
2axi
monomer23-114
2×SO4; 1×MPO;
Assess
Inhibitor of MDM2-p53 Interaction
7bj6
monomer17-108
1×DMS; 2×EDO; 3×SO4; 1×TVK;
Assess
Co-crystal structure of MDM2 with Inhibitor Compound 4
4oba
monomer19-110
1×2TW;
Assess
Structure of a stapled peptide bound to MDM2
6y4q
monomer17-108
1×O9E;
Assess
Inhibitor of MDM2-p53 Interaction
7biv
monomer17-108
2×DMS; 1×EDO; 2×SO4; 1×TUW;
Assess
crystal structure of compound 16 bound to MDM2(17-111), {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP…
4qoc
monomer19-110
1×35T;
Assess
Inhibitor of MDM2-p53 Interaction
7bmg
monomer17-108
3×EDO; 1×U3Z;
Assess
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 11 AT 2.0A; Structural states of Hdm2 and HdmX: X-…
6q9h
monomer19-110
1×HRH;
Assess
crystal structure of MDM2 (17-111) in complex with compound 29 (AM-8553)
4erf
monomer19-110
1×0R3;
Assess
Inhibitor of MDM2-p53 Interaction
7bir
monomer17-108
2×SO4; 1×TUZ;
Assess
Inhibitor of MDM2-p53 Interaction
7bit
monomer17-108
1×SO4; 1×TV5;
Assess
Co-crystal structure of MDM2 with inhibitor {(2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-[(2…
4jwr
monomer19-110
1×1MY;
Assess
Crystal Structure of HDM2 in complex with Caylin-1
7qdq
monomer20-110
3×CL; 2×NA; 1×SO4; 1×AU0; 2×DMS;
Assess
Crystal Structure of an MDM2/Nutlin-3a complex
4hg7
monomer18-108
1×NUT; 1×SO4;
Assess
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical …
4zyi
monomer20-110
1×4TH; 1×CL;
Assess
Crystal structure of Mdm2 bound to a stapled peptide
6h22
monomer18-108
1×FL5;
Assess
crystal structure of MDM2 (17-111) in complex with compound 23
4ere
monomer22-111
1×0R2; 1×SO4;
Assess
X-ray structure of Mdm2 with modified p53 peptide
7ad0
monomer24-113
Assess
Structure of a novel submicromolar MDM2 inhibitor
3tj2
monomer21-110
1×TJ2; 2×K;
Assess
HDM2 in complex with compound 2
7na1
monomer24-112
1×1GI; 1×SO4; 1×CIT;
Assess
Crystal structure of HIS6-tagged Mdm2 with nutlin-3a
5z02
monomer24-111
1×NUT;
Assess
MDM2 in complex with an 8-mer p53 peptide analogue
2gv2
monomer25-112
Assess
Structure of human MDM2 in complex with an optimized p53 peptide
1t4f
monomer23-110
1×SO4;
Assess
The 1.25A Crystal structure of His6-tagged Mdm2 in complex with nutlin-3a
5zxf
monomer24-110
1×NUT;
Assess
Structure of the MDM2 P53 binding domain in complex with H102, an all-D Helicon Polypeptide
8f10
monomer25-111
4×EDO; 1×CL; 2×GOL; 1×WHL; 1×IMD;
Assess
Crystal structure of hDM2 in complex with a C-terminal triurea capped peptide chimera foldamer.
6hfa
monomer25-111
Assess
Structure of human MDM2 in complex with high affinity peptide
3g03
monomer25-111
Assess
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 12 AT 1.8A; Structural states of Hdm2 and HdmX: X-…
6q96
monomer25-111
1×HRE; 2×SO4;
Assess
Structure of the Stapled p53 Peptide Bound to Mdm2
3v3b
monomer24-110
5×CL;
Assess
X-RAY STRUCTURE OF HDM2/CMR19 AT 1.45A: Discovery, X-ray structure and CPP-conjugation enabled upta…
7nus
monomer26-111
2×SO4;
Assess
Mdm2 in complex with a D amino Acid Containing Stapled Peptide
6aaw
monomer26-111
Assess
Structure of a novel submicromolar MDM2 inhibitor
4mdq
monomer25-110
2×28W;
Assess
HDM2 in complex with a 3,3-Disubstituted Piperidine
5hmk
monomer26-111
1×62Q;
Assess
CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA)
7kjm
monomer25-109
1×PEG; 1×IPA; 2×CL;
Assess
Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity:…
6kzu
monomer25-109
Assess
Crystal structure of human MDM2 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate…
5vk0
monomer25-109
Assess
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…
6t2d
monomer25-109
1×EPE; 1×DMS; 1×M9E;
Assess
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor
3w69
monomer25-109
1×LTZ; 1×SO4;
Assess
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…
6t2f
monomer25-109
1×M9H;
Assess
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorp…
4jv7
monomer26-110
1×1MN; 1×SO4;
Assess
Structure of human MDM2 protein in complex with a small molecule inhibitor
3lbk
monomer26-110
1×K23; 1×SO4;
Assess
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…
6t2e
monomer25-109
Assess
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-chlorophenyl)-4-methylmor…
4jv9
monomer26-110
1×1MO; 2×SO4;
Assess
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor
3vzv
monomer25-109
1×VZV;
Assess
Crystal structure of human MDM2 in complex with a trifluoromethylated D-peptide inhibitor
3tpx
monomer26-109
1×SO4;
Assess
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with…
4zyc
monomer25-108
2×4SS;
Assess
Human MDM2 liganded with a 12mer peptide inhibitor (pDIQ)
3jzs
monomer26-108
1×EDO;
Assess
Structure of the Stapled Peptide Bound to Mdm2
5afg
monomer26-108
1×P07;
Assess
CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3
5umm
monomer27-108
Assess
Crystal structure of human MDM2 complexed with D-peptide (12 residues)
3iwy
monomer26-107
Assess
Solution structure of the C4 zinc-finger domain of HDM2
2c6a
monomer290-335
1×ZN;
Assess
Solution structure of the C4 zinc-finger domain of HDM2
2c6b
monomer290-335
1×ZN;
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5j7f.2.Ahomo-2-mer0.8111-114
2×6GG;100.00
Assess
7ahz.1.Ahomo-2-mer0.76436-490
4×ZN;85.29
Assess

18 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 26sqp.1.Bmonomer0.68229-296
2×ZN;91.18
Assess
Isoform 36sqp.1.Bmonomer0.70203-270
2×ZN;91.18
Assess
Isoform 34xxb.1.Bmonomer0.5377-113
1×ZN;97.78
Assess
Isoform 47ahy.1.Ahomo-2-mer0.75161-217
4×ZN;85.29
Assess
Isoform 44xxb.1.Bmonomer0.5222-61
1×ZN;96.38
Assess
Isoform 57bj0.1.Amonomer0.7617-58
85.71
Assess
Isoform 56sqp.1.Bmonomer0.66254-321
2×ZN;91.18
Assess
Isoform 65mnj.1.Cmonomer0.6770-132
2×ZN;100.00
Assess
Isoform 75j7f.2.Amonomer0.7412-93
84.95
Assess
Isoform 87ahz.1.Ahomo-2-mer0.75375-429
4×ZN;85.29
Assess
Isoform 81ttv.1.Amonomer0.621-56
73.21
Assess
Isoform 97ahz.1.Amonomer0.75391-445
2×ZN;85.29
Assess
Isoform 95j7f.2.Amonomer0.5212-69
100.00
Assess
Isoform 105j7f.2.Ahomo-2-mer0.8111-114
2×6GG;100.00
Assess
Isoform 107ahz.1.Ahomo-2-mer0.77381-435
4×ZN;85.29
Assess
Isoform 115j7f.2.Ahomo-2-mer0.8117-120
2×6GG;100.00
Assess
Isoform 117ahz.1.Ahomo-2-mer0.75442-496
4×ZN;85.29
Assess
Isoform 114xxb.1.Bmonomer0.56299-340
1×ZN;100.00
Assess